Epigenomics AG (LON: 0QXH)

Market Cap	925.14K
Revenue (ttm)	115.50K
Net Income (ttm)	2.51M
Shares Out	n/a
EPS (ttm)	2.87
PE Ratio	0.37
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Average Volume	2,713
Open	1.110
Previous Close	n/a
Day's Range	1.110 - 1.110
52-Week Range	0.748 - 0.922
Beta	n/a
RSI	21.49
Earnings Date	Mar 24, 2025

About Epigenomics AG

Epigenomics AG does not have significant operations. Previously, it was involved in liquid biopsy for the early detection of cancer. The company was founded in 1998 and is based in Heidelberg, Germany.

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1998
• Employees: 6
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QXH

Financial Performance

In 2023, Epigenomics AG's revenue was 339,227, a decrease of -62.27% compared to the previous year's 899,000. Losses were -4.46 million, -74.21% less than in 2022.

Financial numbers in EUR